CN1823760A艾蒿类药物治疗胶质增生的用途---公开了一种青蒿素类药物在口服或注射治疗神经胶质瘤中的应用｜CN1823760A Artemisinin class drugs for the treatment of glioma---discloses the use of artemisinin class drugs for oral or injection treatment of gliomas.
Entry posted by Roger in Artemisinin Patent｜青蒿素专利
81 views
CN1823760A艾蒿类药物治疗胶质增生的用途---公开了一种青蒿素类药物在口服或注射治疗神经胶质瘤中的应用
CN1823760A Artemisinin class drugs for the treatment of glioma---discloses the use of artemisinin class drugs for oral or injection treatment of gliomas.
青蒿素类药物治疗神经胶质瘤的用途
本发明公开了青蒿素类药物的一种新的医药用途，即可以作为一种高效、低毒、价廉的新型化疗药治疗神经胶质瘤。对神经胶质瘤患者和神经胶质瘤手术后复发的患者口服或者注射给药，每天使用10－2000mg(优选50－500mg)的剂量治疗，能够使肿瘤消失或者控制其增殖，使患者能够长期正常生活和工作。
青蒿素类药物治疗神经胶质瘤的用途
技术领域
本发明涉及生物医药领域，特别是涉及青蒿素类药物治疗神经胶质瘤的用途。
背景技术
神经胶质瘤是脑部肿瘤的主要类型之一，神经胶质细胞的非正常分化及恶变是神经胶质瘤的重要成因。虽然已有许多肿瘤化疗药，但由于脑组织毛细血管特有的结构，这些抗肿瘤药往往不能透过血脑屏障儿发挥作用。事实上，目前尚无有效治疗神经胶质瘤的药物。
青蒿素(artemisinin，或qinghaosu或arteannuin)是从药用植物黄花蒿(Artemisia annua L.)中提取的一种化合物。青蒿素类药物是从青蒿素衍生的分子结构中具有含有过氧键和青蒿素母核结构的倍半萜类化合物，包括青蒿素、双氢青蒿素(二氢青蒿素，dihydroartemisinin)、青蒿琥酯(artesunate)、蒿甲醚(artemether)、蒿乙醚(arteether)、蒿立酸盐(artelinate)等，目前作为抗疟药使用，对各种类型的疟疾具有治疗作用，尤其对恶性疟和脑型疟具有特效。这些药物经过长期大例数的疟疾临床运用，还证明在使用剂量下十分安全，几乎无任何毒副作用。
鉴于——青蒿素类药物能有效穿透血脑屏障；青蒿素类药物具有抗肿瘤(如白血病、乳腺癌等)作用；青蒿素类药物毒副作用小，而已有化疗药毒性都很强；青蒿素类药物治疗疟疾无抗药性报道，而一般抗肿瘤化学药易产生抗药性等理由，我们近几年开展了用青蒿素类药物对神经胶质瘤患者包括神经胶质瘤术后复发患者的临床治疗研究。
发明内容
我们在临床试验中令人惊喜地发现：对神经胶质瘤患者和神经胶质瘤手术后复发的患者，采用上述青蒿素类药物的一种(优选青蒿琥酯或双氢青蒿素)进行治疗，能够控制肿瘤的增殖，也能够使患者肿瘤不复发，患者长期存活。取得了满意的疗效。
本发明的目的志在克服现有技术的不足而提供一种针对神经胶质瘤的全新、高效的新治疗药物，具体的说，是青蒿素类药物在制备治疗神经胶质瘤的药物中的用途。
——所述的青蒿素类药物是含有过氧键、具有青蒿素母核结构的倍半萜类化合物及其衍生物，包括青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚、蒿乙醚、蒿立酸盐。
——所述的青蒿素类药物选自青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚。
——所述的青蒿素类药物的质量标准和/或药品说明书中包含对人体神经胶质瘤的用途；
——所述的青蒿素药物的临床适应中包含神经胶质瘤。
——所述的青蒿素类药物治疗神经胶质瘤患者每天的剂量是25-500mg(每天的剂量优选50-500mg)，可1次或多次服用或注射。
本发明的意义在于发现了青蒿素类药物的治疗疟疾作用以外的一种新的医学用途，即可以作为一种高效、低毒、价廉的新型化疗药治疗神经胶质瘤。
具体实施方式
青蒿素类药物口服或者注射，能够有效治疗神经胶质瘤。用青蒿素类药物(优选青蒿琥酯或者双氢青蒿素)治疗神经胶质瘤患者18例，其中14例取得显著疗效，显效率达77.8％。
实施例1
某甲，男，成年，1998年经CT诊断，确诊为神经胶质瘤，同年9月对所患神经胶质瘤实施手术治疗。但2001年8月CT检查发现肿瘤复发，2003年3月起停服原先服用的药物，改为服用青蒿琥酯100mg/日，连服2年，2004年11月CT检查，神经胶质瘤消失，且未见任何不良反应，至今患者生活如常。
实施例2
某乙，男，成年，1994年发现患神经胶质瘤并实施手术治疗，2005年1月复发，使用伽玛射线进行姑息治疗，但无效果。2005年3月起口服青蒿琥酯300mg/日，连服4个月，MRI诊断发现肿瘤消失，维持100mg/日剂量治疗，患者能够正常生活工作。治疗期间未见任何不良反应。
1、青蒿素类药物在制备治疗神经胶质瘤的药物中的用途。
2、根据权利要求1所述的用途，其特征在于所述的青蒿素类药物是含有过氧键、具有青蒿素母核结构的倍半萜类化合物及其衍生物，包括青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚、蒿乙醚、蒿立酸盐。
3根据权利要求1所述的用途，其特征在于所述的青蒿素类药物选自青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚。
4、根据权利要求1所述的用途，其特征在于所述的青蒿素类药物的质量标准和/或药品说明书中包含对人体神经胶质瘤的用途。
5、根据权利要求1所述的用途，其特征在于所述的青蒿素类药物的临床适应症中包含神经胶质瘤。
6、根据权利要求1所述的用途，其特征在于所述的青蒿素类药物治疗神经胶质瘤患者时，每天的剂量是10-2000mg(每天的剂量优选50-500mg)，可1次或多次服用或注射。
Use of artemisia apiacea kind medicine for treating gliosis
An application of arteannuin-kind medicines in treating neuroglioma by oral taking or injection is disclosed.
The purposes of artemisia apiacea kind medicine for treating gliosis
Technical field
The present invention relates to biomedicine field, particularly relate to the purposes of artemisia apiacea kind medicine for treating gliosis.
Background technology
Glioma is one of main type of brain tumor, the improper differentiation of neurogliocyte and to cancerate be the gliomatous important origin cause of formation.Though existing many chemotherapy of tumors medicines, because cerebral tissue blood capillary its specific structure, these antineoplastic agents often can not see through blood brain barrier and play a role.In fact, still there is not the effectively gliomatous medicine of treatment at present.
Arteannuin (artemisinin, or qinghaosu or arteannuin) is a kind of chemical compound that extracts from medicinal plants Herba Artemisiae annuae (Artemisia annua L.).Artemisinin-based drug is to have the sesquiterpenoids that contains peroxide bridge and arteannuin mother nucleus structure from the deutero-molecular structure of arteannuin, comprise arteannuin, dihydroarteannuin (dihydroartemisinine, dihydroartemisinin), artesunate (artesunate), Artemether (artemether), arteether (arteether), the upright hydrochlorate (artelinate) of Artemisia etc., use as antimalarial at present, various types of malaria are had therapeutical effect, especially subtertian malaria and cerebral malaria are had specially good effect.These medicines also prove under using dosage fool proof, almost without any side effects through the malaria clinical application of long-term big routine number.
In view of---artemisinin-based drug can effectively penetrate blood brain barrier; Artemisinin-based drug has antitumor (as leukemia, breast carcinoma etc.) effect; The artemisinin-based drug toxic and side effects is little, and existing chemotherapeutic toxicity is all very strong; Artemisinin-based drug treatment malaria does not have the Drug resistance report, and general antitumor chemistry medicine reason such as easily develop immunity to drugs, we had carried out the clinical treatment research that the glioma patient is comprised glioma postoperative recurrence patient with artemisinin-based drug in recent years.
Summary of the invention
We surprisedly find in clinical trial: to the patient of glioma patient and glioma recurrence after operation, adopt a kind of (the preferred artesunate or the dihydroarteannuin) of above-mentioned artemisinin-based drug to treat, can control the propagation of tumor, also can make patient tumors not recur patient's long-term surviving.Obtained satisfied curative effect.
Purpose of the present invention aim at overcoming the deficiencies in the prior art and provide a kind of at gliomatous completely newly, new medicine efficiently, specifically, be the purposes of artemisinin-based drug in the gliomatous medicine of preparation treatment.
---described artemisinin-based drug is sesquiterpenoids and the derivant thereof that contains peroxide bridge, has the arteannuin mother nucleus structure, comprises arteannuin, dihydroarteannuin, artesunate, Artemether, arteether, the upright hydrochlorate of Artemisia.
---described artemisinin-based drug is selected from arteannuin, dihydroarteannuin, artesunate, Artemether.
---comprise purposes in the quality standard of described artemisinin-based drug and/or the package insert to the human nerve glioma;
---comprise glioma in the clinical adaptation of described arteannuin medicine.
---the dosage of described artemisia apiacea kind medicine for treating gliosis patient every day is 25-500mg (the preferred 50-500mg of the dosage of every day), can 1 time or repeatedly take or inject.
Meaning of the present invention has been to find a kind of new medical usage beyond the treatment malaria effect of artemisinin-based drug, promptly can be as a kind of efficient, low toxicity, inexpensive novel chemotherapeutic treatment glioma.
The specific embodiment
Glioma can be effectively treated in the oral or injection of artemisinin-based drug.With artemisinin-based drug (preferred artesunate or dihydroarteannuin) treatment glioma patient 18 examples, wherein 14 examples obtain significant curative effect, and obvious effective rate reaches 77.8%.
Embodiment 1
Certain person, the man grows up, and is diagnosed as glioma through the CT diagnosis in 1998, and the same year, JIUYUE was to suffering from glioma enforcement operative treatment.But August calendar year 2001, CT examination was found tumor recurrence, and rise and withdraw the medicine of originally taking in March, 2003, changes into and taking artesunate 100mg/ day, serve on 2 years, in November, 2004 CT examination, glioma disappears, and do not see any untoward reaction, the patient lives as usual so far.
Embodiment 2
Certain second, the man grows up, and finds to suffer from glioma and implement operative treatment in 1994, and in January, 2005 recurrence uses gamma ray to carry out palliative treatment, but to no effect.Rise oral artesunate 300mg/ day in March, 2005, serve on 4 months, and the MRI diagnosis finds that tumor disappears, and keeps the treatment of 100mg/ daily dose, and the patient can work orthobiosis.Do not see any untoward reaction during the treatment.
1, the purposes of artemisinin-based drug in the gliomatous medicine of preparation treatment.
2, purposes according to claim 1, it is characterized in that described artemisinin-based drug is sesquiterpenoids and the derivant thereof that contains peroxide bridge, has the arteannuin mother nucleus structure, comprise arteannuin, dihydroarteannuin, artesunate, Artemether, arteether, the upright hydrochlorate of Artemisia.
3 purposes according to claim 1 is characterized in that described artemisinin-based drug is selected from arteannuin, dihydroarteannuin, artesunate, Artemether.
4, purposes according to claim 1 is characterized in that comprising in the quality standard of described artemisinin-based drug and/or the package insert purposes to the human nerve glioma.
5, purposes according to claim 1 is characterized in that comprising glioma in the clinical indication of described artemisinin-based drug.
6, purposes according to claim 1, when it is characterized in that described artemisia apiacea kind medicine for treating gliosis patient, the dosage of every day is 10-2000mg (the preferred 50-500mg of the dosage of every day), can 1 time or repeatedly take or inject.
0 Comments
Recommended Comments
There are no comments to display.